XML 76 R35.htm IDEA: XBRL DOCUMENT v3.25.0.1
Collaborative Arrangements (Tables)
 12 Months Ended
Dec. 31, 2024
Collaborative Arrangements [Abstract]  
Collaborative Arrangements
Summarized financial information related to this collaboration is as follows:
Years Ended December 31202420232022
Alliance revenue - Lynparza$1,311 $1,199 $1,116 
Alliance revenue - Koselugo170 97 54 
Total alliance revenue$1,481 $1,296 $1,170 
Cost of sales (1)
378 311 492 
Selling, general and administrative165 192 185 
Research and development77 79 106 
December 3120242023
Receivables from AstraZeneca included in Other current assets
$424 $341 
Payables to AstraZeneca included in Accrued and other current liabilities (2)
713 256 
Payables to AstraZeneca included in Other Noncurrent Liabilities (2)
— 600 
(1)    Represents amortization of capitalized milestone payments. Amounts in 2024 and 2022 include $48 million and $250 million, respectively, of cumulative amortization catch-up expense as noted above.
(2)    Includes accrued milestone payments.
Summarized financial information related to this collaboration is as follows:
Years Ended December 31202420232022
Alliance revenue - Lenvima$1,010 $960 $876 
Cost of sales (1)
241 381 212 
Selling, general and administrative159 189 158 
Research and development21 66 136 
December 3120242023
Receivables from Eisai included in Other current assets
$257 $226 
Payables to Eisai included in Accrued and other current liabilities (2)
— 125 
(1)     Represents amortization of capitalized milestone payments. Amount in 2023 includes $154 million of cumulative amortization catch-up expense as noted above.
(2)     Represents an accrued milestone payment.
Summarized financial information related to this collaboration is as follows:
Years Ended December 31202420232022
Alliance revenue - Adempas/Verquvo$415 $367 $341 
Net sales of Adempas recorded by Merck287 255 238 
Net sales of Verquvo recorded by Merck37 36 22 
Total sales$739 $658 $601 
Cost of sales (1)
244 224 210 
Selling, general and administrative111 131 153 
Research and development102 90 75 
December 3120242023
Receivables from Bayer included in Other current assets
$160 $156 
Payables to Bayer included in Accrued and other current liabilities
82 80 
(1)    Includes amortization of intangible assets, cost of products sold by Merck, as well as Bayer’s share of profits from sales in Merck’s marketing territories.
Summarized financial information related to this collaboration is as follows:
Years Ended December 31202420232022
Net sales of Lagevrio recorded by Merck
$964 $1,428 $5,684 
Cost of sales (1)
554 852 3,038 
Selling, general and administrative
57 97 147 
Research and development
13 60 88 
December 3120242023
Payables to Ridgeback included in Accrued and other current liabilities (2)
$68 $113 
(1)    Includes cost of products sold by Merck, Ridgeback’s share of profits, royalty expense, amortization of capitalized milestone payments and inventory reserves.
(2)    Includes accrued royalties.
Summarized financial information related to this collaboration is as follows:
Years Ended December 3120242023
Selling, general and administrative
$26 $3 
Research and development (1)
351 5,549 
December 3120242023
Receivables from Daiichi Sankyo included in Other current assets
$8 $— 
Payables to Daiichi Sankyo included in Accrued and other current liabilities (2)
817 800 
Payables to Daiichi Sankyo included in Other Noncurrent Liabilities (2)
— 750 
(1)    Expenses in 2023 include the $5.5 billion charge for the upfront and continuing option payments noted above.
(2)    Includes accrued continuation payment.
Summarized financial information related to this collaboration is as follows:
Years Ended December 31202420232022
Selling, general and administrative
$16 $5 $— 
Research and development (1)
358 218 288 
December 3120242023
Payables to Moderna included in Accrued and other current liabilities
$57 $63 
(1)    Expenses in 2022 include the $250 million option exercise payment noted above.